LONDON, England, Sept. 15 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:

* * *

GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences

* Trispecific TCE targeting T cells and two tumour antigens has potential for differentiated efficacy and safety over current TCEs

* Programme to enter clinic in 2027

* Deal aligned to GSK's p . . .

Click here for more information about our products